Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Friday October 16, 2009

DrStockPick.com Stock Report!

**************************************************************

Cavitation Technologies, Inc. (CTI) (OTC Bulletin Board: CVAT) has signed Miura Engineering Co., Ltd. Tokyo, Japan (www.miura21.co.jp) as its new agent to serve markets in Japan for CTI’s Nano-Cavitation Process Systems. Miura is a leading Engineering Company specialized in Edible Oil Processing Plants in the Far East.

Applied Signal Technology, Inc. (NASDAQ:APSG), a market leader in advanced intelligence, surveillance, and reconnaissance (ISR) solutions, today announced that it will showcase an extensive collection of next-generation, tactical

...

Early Wednesday afternoon, Merck announced that they have made a decision of research collaboration with Galapagos NV. The news about the research collaboration had positive responses from analysts and the shares of Merck went up shortly after the announcement was made. Building on the deal struck at the very beginning of the year, Merck has boosted its commitment on milestones for new atherosclerosis therapies for more than 400 million Euros. Galapagos NV was founded ten years ago as a joint venture between Crucell and Tibotec. The company has always adopted hybrid business model and have come up quickly raising funds through private placements and public offerings.

As per the strategic alliance between Merck and Galapagos for the development of new therapies for atherosclerosis, Galapagos VN will be responsible for the discovery

...

Dr Stock Pick HOT News & Alerts!

_______________________________________

FREE Daily Stock Alerts From DrStockPick.com

_______________________________________

Wednesday October 14, 2009

DrStockPick.com Stock Report!

**************************************************************

SolarWinds® (NYSE: SWI), a leading provider of powerful, simple and affordable network management software to more than 85,000 customers worldwide, today announced that it has further simplified and expanded the company’s online purchase experience, giving companies 24/7 direct access to products, from anywhere around the world.

China Aoxing Pharmaceutical Company, Inc. (OTCBB: CAXG), a China-based pharmaceutical company specializing in research, development, manufacturing and distribution of narcotic and pain-management products, today announced financial results for the fiscal

...

DrStockPick.com Stock Report!

Thursday September 10, 2009

**************************************************************

SigmaTron International, Inc. (Nasdaq:SGMA), an electronic manufacturing services company, today reported revenues and earnings for the fiscal quarter ended July 31, 2009. Revenues decreased to $26.3 million in first quarter of fiscal 2010 from $38.5 million for the same quarter in the prior year. Net income decreased to a loss of ($402,475) for the period ended July 31, 2009 compared to a profit of $579,324 for the same period in the prior year. Basic earnings (loss) per share and diluted earnings (loss) per share from operations for the quarter ended July 31, 2009, were both ($0.11), compared

...

Last week, Array BioPharma Inc. (ARRY) reported a fourth-quarter net loss of 55 cents per share which was in line with the Zacks Consensus Estimate. The company had a loss of 68 cents in the year-ago quarter. Net loss for fiscal 2009 was $2.67 per share, compared with $2.04 last year.

Quarterly revenue came in at $5.5 million, representing a 10% decline from the comparable quarter in 2008. Sales for the full year fell by 13% to $25 million.

The narrower quarterly loss was primarily attributable to lower spending on research and development. The company spent $21.3 million towards research and development for the quarter for the clinical advancement of its wholly owned drugs versus $28.4 million in year-ago quarter.

Last January, Array had announced a restructuring plan of scaling down its research and development costs and accelerating partnership initiatives to ensure sustainable growth under current market conditions.

...

DrStockPick.com Stock Report!

Tuesday August 4, 2009

**************************************************************

Varian Semiconductor Equipment Associates, Inc. (NASDAQ: VSEA) today announced that the company will deliver a presentation at the 11th Annual Pacific Crest Technology Leadership Forum in Vail, Colorado on Tuesday, August 11, 2009 at 9:30 am mountain time.

Allied Motion Technologies Inc. (NASDAQ: AMOT) today announced it had a net loss for the quarter ended June 30, 2009 of $12,115,000 or $1.60 per diluted share compared to net income of $1,001,000 or $.13 per diluted share for the quarter ended June 30, 2008, a quarter in which the Company achieved record sales and profits. The loss includes a pretax asset impairment charge of $15,986,000 ($11,105,000

...

For Immediate Release

Chicago, IL - April 27, 2009 - Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Lockheed Martin Corp (LMT), Schlumberger, Ltd. (SLB), Halliburton's (HAL), deCODE genetics, Inc. (DCGN) and Celera Corp. (CRA).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579.

Here are highlights from Friday's Analyst Blog:

Lockheed Beats & Ups Guidance

Lockheed Martin Corp (LMT) reported a 1st quarter 2009 profit of $666 million, down 9% from $730 million in the 1st quarter of 2008.

On a per-share basis, the reported result was $1.68 per diluted share, down 4% from $1.75 per diluted share

...

 Yesterday (Thursday), deCODE genetics, Inc. (DCGN) announced that the company signed an agreement with Celera Corp. (CRA). Pursuant to the agreement, deCODE granted Celera non-exclusive worldwide licenses to deCODE's genetic markers for increased risk of major cardiovascular and metabolic diseases, including heart attack, stroke, atrial fibrillation (AF) and type II diabetes. These markers can be incorporated into laboratory tests for assessing and managing individual risk of these diseases.The deCODE markers include single letter variations in the human genome (SNPs) on chromosome 9p21 linked to increased risk of heart attack and aortic aneurysm, SNPs on chromosome 4q25 conferring risk of AF and stroke, and SNPs in the TCF7L2 gene linked to increased risk of type II diabetes. Studies by deCODE and independent academic groups have demonstrated the utility of testing for these markers to better understand individual risk and to inform more effective and personalized prevention ...

RXi Pharmaceuticals Corporation (NASDAQ: RXII) reported today that it has hired Dr. Anastasia Khvorova to fill the new post of Chief Scientific Officer (CSO). RXi Pharmaceuticals expects to benefit from the six years of experience Khvorova gained in the development and supply of RNAi compounds in her last job as CSO of Dharmacon, Inc.

According to company President and CEO, Dr. Tod Woolf, Khvorova’s appointment adds to the scope and depth of RXi’s talent in the RNAi field. “Among her many accomplishments,” noted Woolf, “Dr. Khvorova’s group at Dharmacon designed and manufactured RNAi compounds targeting virtually all of the known human genes. Moreover, Dr. Khvorova is one of the most widely cited authors of research articles in the field of RNAi, which serves as a testament to the impact her work has had in the field. Through her ground-breaking research, Dr. Khvorova also developed “self-delivering” RNAi compounds

...